菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletters

At WuXi Biologics, we put customers first by embracing change and driving innovation to execute their drug development needs and expedite their timelines. Our research, development, and manufacturing capabilities along with our global footprint are continuously expanded to help our partners to effectively and efficiently bring biologics and vaccines to patients worldwide. We are pleased to provide you with periodic summaries that may be useful as you move through your product lifecycle or are starting out at the discovery phase.

We are pleased to provide you a summary of the relevant updates on our services, operations, awards, and other initiatives to support your efforts to stay current with the biological therapeutics and vaccines industry.

The WuXi Biologics’ Regulatory Affairs team is honored to provide you on a quarterly basis with a summary of what we deem as the relevant (i.e., product development and CMC-related) regulatory updates that are either in draft or final status by agency and by topic. The intent of these updates is to provide the global regulatory agencies’ (e.g., U.S. FDA, EMA, NMPA, ICH, HSA, ANVISA, PMDA, MFDS, TGA, Health Canada etc.) updates and new or revised documents during the period stated in the corresponding webpages. We have compiled these updates to support your efforts to stay current in the ever-changing regulatory environment for biological therapeutics and vaccines.